Gastroenterology
1 drug is in development for NASH - Nonalcoholic Steatohepatitis.
- Companies
- 1
- Clinical trials
- 11
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the NASH - Nonalcoholic Steatohepatitis pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 1(1)
| Drug | Company |
|---|---|
| belapectin | GALECTIN THERAPEUTICS INC (GALT) |
About this indication
NASH - Nonalcoholic Steatohepatitis context
Gastroenterology·MeSH: Non-alcoholic Fatty Liver Disease (D065626)
Narrower concept of MeSH descriptor NAFLD
Prevalence
5000.0 / 100K
Incidence
500.0 / 100K/yr
Frequently asked questions
How many drugs are in development for NASH - Nonalcoholic Steatohepatitis?
BioSniper tracks 1 drug in development for NASH - Nonalcoholic Steatohepatitis across 1 company.
How many clinical trials target NASH - Nonalcoholic Steatohepatitis?
There are 11 clinical trials targeting NASH - Nonalcoholic Steatohepatitis tracked by BioSniper.
What is the prevalence of NASH - Nonalcoholic Steatohepatitis?
The estimated prevalence of NASH - Nonalcoholic Steatohepatitis is approximately 5000.0 per 100,000 population.